Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 13/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5545341 | 0.87 | ALDH1A1 (0.45) | KDM4EALDH1A1MEN1KMT2ANPC1 | |
| SCHEMBL14511060 | 0.85 | MEN1 (0.40) | KDM4EHIF1AMEN1KMT2ANPC1 | |
| SCHEMBL14536652 | 0.85 | KDM4E (0.47) | KDM4EHIF1AMEN1KMT2ANPC1 | |
| SCHEMBL14536651 | 0.84 | MEN1 (0.39) | KDM4EALDH1A1HPGDHIF1AMEN1 | |
| SCHEMBL5541153 | 0.84 | HIF1A (0.39) | HIF1AMEN1KMT2AGRIN2B | |
| SCHEMBL5545343 | 0.83 | MEN1 (0.36) | KDM4EALDH1A1HPGDHIF1AMEN1 | |
| SCHEMBL4576606 | 0.81 | MEN1 (0.37) | KDM4EALDH1A1HPGDHIF1AMEN1 | |
| SCHEMBL5548083 | 0.81 | MEN1 (0.35) | KDM4EALDH1A1HPGDHIF1AMEN1 | |
| SCHEMBL4591362 | 0.79 | MEN1 (0.34) | KDM4EALDH1A1HPGDHIF1AMEN1 | |
| SCHEMBL5546555 | 0.79 | HDAC3 (0.38) | HIF1AMEN1KMT2AGRIN2BEGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150225399-A1 | HIV INTEGRASE INHIBITORS | VIIV HEALTHCARE CO (US) | 2015-08-13 | — | — | US | disclosed |
| US-20140256713-A1 | 2-OXONAPHTHYRIDINE-3-CARBOXAMIDES HIV INTEGRASE INHIBITORS | SHIONOGI & CO., LTD. (JP) | 2014-09-11 | — | — | US | disclosed |
| EP-1720856-B1 | HIV INTEGRASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2013-08-14 | — | — | EP | disclosed |
| US-20070124152-A1 | Hiv Integrase Inhibitors | GLAXOSMITHKLINE LLC | 2007-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140256713-A1 | 2-OXONAPHTHYRIDINE-3-CARBOXAMIDES HIV INTEGRASE INHIBITORS | BCDIN3D, DUT, SAMHD1 | KDM4E 1268/4885ALDH1A1 3812/4885HPGD 3518/4885 |
| US-20150225399-A1 | HIV INTEGRASE INHIBITORS | ING2, API5, SAMHD1 | KDM4E 1255/4885ALDH1A1 3073/4885HPGD 2929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.